- Home
- SEAT vs MLYS Comparison
SEAT vs MLYS Comparison
Compare SEAT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- MLYS
- Stock Information
- Founded
- SEAT 2001
- MLYS 2019
- Country
- SEAT United States
- MLYS United States
- Employees
- SEAT N/A
- MLYS N/A
- Industry
- SEAT Industrial Machinery/Components
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SEAT Industrials
- MLYS Health Care
- Exchange
- SEAT Nasdaq
- MLYS Nasdaq
- Market Cap
- SEAT 622.1M
- MLYS 634.6M
- IPO Year
- SEAT N/A
- MLYS 2023
- Fundamental
- Price
- SEAT $4.70
- MLYS $9.97
- Analyst Decision
- SEAT Strong Buy
- MLYS Strong Buy
- Analyst Count
- SEAT 10
- MLYS 2
- Target Price
- SEAT $6.73
- MLYS $30.00
- AVG Volume (30 Days)
- SEAT 1.2M
- MLYS 254.8K
- Earning Date
- SEAT 03-04-2025
- MLYS 03-20-2025
- Dividend Yield
- SEAT N/A
- MLYS N/A
- EPS Growth
- SEAT N/A
- MLYS N/A
- EPS
- SEAT N/A
- MLYS N/A
- Revenue
- SEAT $774,076,000.00
- MLYS N/A
- Revenue This Year
- SEAT $10.17
- MLYS N/A
- Revenue Next Year
- SEAT $4.02
- MLYS N/A
- P/E Ratio
- SEAT $27.68
- MLYS N/A
- Revenue Growth
- SEAT 13.91
- MLYS N/A
- 52 Week Low
- SEAT $3.24
- MLYS $8.58
- 52 Week High
- SEAT $6.41
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- SEAT 62.13
- MLYS 40.13
- Support Level
- SEAT $4.49
- MLYS $9.18
- Resistance Level
- SEAT $5.00
- MLYS $10.71
- Average True Range (ATR)
- SEAT 0.22
- MLYS 0.84
- MACD
- SEAT -0.01
- MLYS -0.05
- Stochastic Oscillator
- SEAT 57.14
- MLYS 28.72
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.